Trial Search Results

Responses to Influenza Vaccine in Patients With Mitochondrial Disorders (MELAS)

This pilot clinical study evaluated the safety and metabolic responses to a licensed inactivated seasonal influenza vaccine (TIV) in mitochondrial encephalopathy, lactic acidosis, and stroke-like episodes syndrome (MELAS) volunteers and controls.

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

Stanford University

Collaborator: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

Stanford Investigator(s):

Intervention(s):

  • Biological: Fluzone®

Phase:

Phase 4

Eligibility


Inclusion Criteria:Inclusion criteria include:

   - Age between 13-60 years for MELAS volunteers OR age between 18-65 years for adult
   control volunteers. Control volunteers will be age-matched +/-5 years to enrolled
   MELAS volunteers. If the MELAS volunteer has diabetes and uses insulin daily, their
   control will be an adult with diabetes who uses insulin daily.

   - General good health at time of enrollment

   - Willing and able to sign Informed Consent

   - Available for follow-up for the planned duration of the study

   - Acceptable medical history by screening evaluation and brief clinical assessment

   - All female participants of childbearing potential must use an acceptable method of
   contraception and not become pregnant for the duration of the clinical phase of the
   study (approximately 1 month to completion of Visit 4). (Acceptable contraception may
   include but is not limited to implants, injectables, combined oral contraceptives,
   effective intrauterine devices (IUDs), sexual abstinence, or a vasectomized partner).

Exclusion Criteria:Exclusion criteria will include:

   - Allergy to egg or egg products or allergy to vaccine components, including thimerosal

   - Active systemic or serious concurrent illness, including febrile illness, within the 3
   days prior to study vaccination

   - History of immunodeficiency, known or suspected impairment of immunologic function,
   including, but not limited to, clinically significant liver disease, moderate to
   severe renal disease, or any other chronic disorder which, in the opinion of the
   investigator, might jeopardize volunteer safety or compliance with the protocol.

   - Blood pressure >150 systolic or >95 diastolic at Visit 1.

   - Hospitalization in the past year for congestive heart failure or emphysema.

   - History of chronic Hepatitis B or C.

   - Recent or current use of immunosuppressive medication, including glucocorticoids
   (corticosteroid nasal sprays are permissible).

   - Malignancy, other than squamous cell or basal cell skin cancer (includes solid tumors
   such as breast cancer or prostate cancer with recurrence in the past year, and any
   hematologic cancer such as leukemia).

   - Autoimmune disease (including rheumatoid arthritis treated with immunosuppressive
   medication such as Plaquenil, methotrexate, prednisone, Enbrel) which, in the opinion
   of the investigator, might jeopardize volunteer safety or compliance with the
   protocol.

   - History of blood dyscrasias, renal disease, or hemoglobinopathies requiring regular
   medical follow up or hospitalization during the preceding year

   - Receipt of blood or blood products within the past 6 months

   - Medical or psychiatric condition or occupational responsibilities that preclude
   subject compliance with the protocol

   - Inactivated vaccine 14 days prior to vaccination or live, attenuated vaccine within 60
   days of vaccination

   - History of Guillain-Barré Syndrome

   - Pregnant or lactating woman

   - Use of investigational agents within 30 days prior to enrollment

   - Donation of the equivalent of a unit of blood within 6 weeks prior to enrollment

   - Any condition which, in the opinion of the investigator, might interfere with
   volunteer safety, study objectives or the ability of the participant to understand or
   comply with the study protocol.

Ages Eligible for Study

13 Years - 65 Years

Genders Eligible for Study

All

Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Greg Enns, MD
(650) 498-5798
Not Recruiting